Working... Menu

Allograft Adipose Matrix (AAM) in Subcutaneous Dorsal Wrist

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02445118
Recruitment Status : Completed
First Posted : May 15, 2015
Last Update Posted : August 10, 2016
Information provided by (Responsible Party):
Musculoskeletal Transplant Foundation

Brief Summary:
This is a 16 week pilot study to assess short term outcomes of an injectable allograft adipose matrix (AAM) in the subcutaneous space in the dorsum of the wrist. A total of 30 patients will be enrolled at 2 sites and will be followed for sixteen weeks. Volume retention and local skin changes will be observed and documented prior to and following injection at week 0 and at follow up visits at 2, 10 and 16 weeks. Evaluations will be done via photographic analysis at week 0,2,10 and 16 weeks and half of the patients will undergo magnetic resonance imaging at week zero and at week 16. The dominant wrist will serve as a control and will receive no injection. Analysis includes volume retention, tissue analysis, local skin changes and adverse events, if any.

Condition or disease Intervention/treatment
Aesthetic Rejuvenation Other: Adipose Allograft Matrix (AAM) injection

Detailed Description:
This pilot study focuses on three primary objectives: to evaluate volume retention at the site of injected allograft adipose matrix (AAM), to obtain tissue analysis via magnetic resonance imaging at the site of injection and to evaluate local skin changes as a result of the injection of AAM with follow up over a 16 week period. The AAM is derived from cadaveric human adipose recovered, processed, dehydrated and distributed by the study sponsor from thoroughly screened donors. It is distributed with instructions for rehydration prior to single use. The injection site (non-dominant wrist) will be infiltrated with Lidocaine 0.5%, Epinepherine 1:200,000 prior to AAM injection. Volume of AAM necessary to create a centered 2-3mm raised wheal at the first proximal dorsal wrist crease will be administered. Photographs taken prior and following the injection and at each of the subsequent visits are taken with a color standard within the frame for later color change analysis of the injection surrounding area. Both the control and treated hand/wrist will be photographed separately in numerous positions (extension, flexion and several degrees of either) at heart level, at week 0,2,10 and 16 weeks. A clinical assessment scale for evaluation of skin changes in appearance will also be done at these same times. Patients will be advised to avoid prolonged pressure to the dorsal wrists, wear no jewelry or wrist bands, etc., for the duration of their participation in the study. Those patients designated for MR imaging shall have their MRIs done within 3 to 5 days of their week zero and week16 visits. The images shall be read and documented by a single independent radiologist.

Layout table for study information
Study Type : Observational
Actual Enrollment : 15 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Local Skin and Volume Changes With the Use of Allograft Adipose Matrix (AAM) in the Subcutaneous Human Dorsal Wrist, a Pilot Study
Study Start Date : May 2015
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016

Group/Cohort Intervention/treatment
Adipose Allograft Matrix Injection
AAM injected to create a 2 to 3mm raised wheal on the proximal dorsal wrist of the non-dominant hand
Other: Adipose Allograft Matrix (AAM) injection
Adipose Allograft Matrix (AAM) injection, Non-dominant wrist

Primary Outcome Measures :
  1. 2-3mm raised wheal volume retention in dorsal wrist injected with AAM at 16 weeks [ Time Frame: 16 weeks ]
    Using a volume assessment scale photographs of treated vs. non-treated dorsal wrist will be evaluated by three plastic surgeons, with mean outcomes for each patient documented as final evidence

Secondary Outcome Measures :
  1. Sub-Dermal Tissue Analysis [ Time Frame: 16 weeks ]
    Magnetic resonance imaging taken at pre-injection (Week 0) and at 16 weeks of treated and non treated dorsal wrists will be evaluated by an independent radiologist for sub dermal adipose persistence

  2. Local skin changes [ Time Frame: 16 weeks ]
    via clinical observation and photographic evidence taken at pre-injection and at pre and post week 0, 2,10 and 16 weeks of treated and non treated dorsal wrists. local skin changes such as pore size, redness, swelling will be documented by study surgeon

  3. Volume retention during the study interim period, documented at weeks 2 and 10 [ Time Frame: 8 weeks ]
    Using a volume assessment scale, photographs of treated vs. non-treated dorsal wrist will be evaluated by three plastic surgeons, using data collected at interim time points during the study; specifically, week 2 and week 10

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Non-smoking females between 45 and 65 years of age with a BMI <30, with well controlled blood pressure, no active infections, collagen disorders,vascular diseases, history of lymphedema, mastectomy, lymph node dissection, end stage organ failure such as COPD, CRF, or CHF, and who have not undergone deep chemical peels, laser, Ultherapy, Thermage or other light or energy based procedures to the dorsum of the hands within the past year.

Inclusion Criteria:

  • Female,
  • Between 35 and 75 years of age,
  • Well controlled blood pressure,
  • Able to sign an informed consent

Exclusion Criteria:

  • Patients with active infection,
  • Patients with a body weight change of greater than 5% throughout the 16 weeks of their participation,
  • Patients with a BMI of greater than 30,
  • Patients with a collagen vascular disease,
  • Patients with end-stage organ failure (advanced COPD, CRF, CHF),
  • Patients with lymphedema or mastectomy or axillary lymph node dissection, Patients who smoke,
  • Patients that have undergone deep chemical peels, lasers, Ultherapy, Thermage, other light or energy based procedures to the dorsum of the hands one year prior,
  • Patients who have taken any medication or oral supplements for the previous 4 weeks that could prolong bleeding time (e.g; Aspirin, Plavix, nutritional supplements starting with G, omega-3 , fish oil, etc)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02445118

Layout table for location information
United States, Florida
Miami Hand Center
Key Biscayne, Florida, United States, 33149
United States, New York
Tribeca Plastic Surgery
New York, New York, United States, 10013
Sponsors and Collaborators
Musculoskeletal Transplant Foundation
Layout table for investigator information
Principal Investigator: Sydney R. Coleman, MD Study Principal Investigator
Principal Investigator: Roger K Khouri, MD Study Principal Investigator

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Musculoskeletal Transplant Foundation Identifier: NCT02445118     History of Changes
Other Study ID Numbers: MTF 184N
First Posted: May 15, 2015    Key Record Dates
Last Update Posted: August 10, 2016
Last Verified: May 2015
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Musculoskeletal Transplant Foundation:
adipose, allograft